CovidChloroV1, Main, Exploration, bibRecord, 000479

Focus on clinical outcomes of "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial".

Identifieur interne : 000479 ( Main/Exploration ); précédent : 000478; suivant : 000480

Focus on clinical outcomes of "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial".

Auteurs : Carlos Gustavo Wambier [États-Unis]

Source :

International journal of antimicrobial agents [ 1872-7913 ] ; 2021.

RBID : pubmed:33408021

Descripteurs français

KwdFr :
- Antibactériens (usage thérapeutique), Antipaludiques (usage thérapeutique), Antiviraux (usage thérapeutique), Association médicamenteuse (MeSH), Azithromycine (usage thérapeutique), Essais cliniques comme sujet (MeSH), Humains (MeSH), Hydroxychloroquine (usage thérapeutique), Incertitude (MeSH), Repositionnement des médicaments (MeSH).
MESH :
- usage thérapeutique : Antibactériens, Antipaludiques, Antiviraux, Azithromycine, Hydroxychloroquine.
- Association médicamenteuse, Essais cliniques comme sujet, Humains, Incertitude, Repositionnement des médicaments.

English descriptors

KwdEn :
- Anti-Bacterial Agents (therapeutic use), Antimalarials (therapeutic use), Antiviral Agents (therapeutic use), Azithromycin (therapeutic use), COVID-19 (drug therapy), COVID-19 (virology), Clinical Trials as Topic (MeSH), Drug Combinations (MeSH), Drug Repositioning (MeSH), Humans (MeSH), Hydroxychloroquine (therapeutic use), SARS-CoV-2 (pathogenicity), Uncertainty (MeSH).
MESH :
- chemical , therapeutic use : Anti-Bacterial Agents, Antimalarials, Antiviral Agents, Azithromycin, Hydroxychloroquine.
- drug therapy : COVID-19.
- pathogenicity : SARS-CoV-2.
- virology : COVID-19.
- Clinical Trials as Topic, Drug Combinations, Drug Repositioning, Humans, Uncertainty.

DOI: 10.1016/j.ijantimicag.2020.106175
PubMed: 33408021
PubMed Central: PMC7779256

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000537
to stream Main, to step Curation: 000537

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Focus on clinical outcomes of "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial".</title>
<author><name sortKey="Wambier, Carlos Gustavo" sort="Wambier, Carlos Gustavo" uniqKey="Wambier C" first="Carlos Gustavo" last="Wambier">Carlos Gustavo Wambier</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Dermatology, Brown University, Warren Alpert School of Medicine, Providence, Rhode Island. Electronic address: carlos_wambier@brown.edu.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Rhode Island</region>
<settlement type="city">Providence (Rhode Island)</settlement>
</placeName>
<wicri:cityArea>Department of Dermatology, Brown University, Warren Alpert School of Medicine, Providence</wicri:cityArea>
<orgName type="university">Université Brown</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2021">2021</date>
<idno type="RBID">pubmed:33408021</idno>
<idno type="pmid">33408021</idno>
<idno type="doi">10.1016/j.ijantimicag.2020.106175</idno>
<idno type="pmc">PMC7779256</idno>
<idno type="wicri:Area/Main/Corpus">000537</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000537</idno>
<idno type="wicri:Area/Main/Curation">000537</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000537</idno>
<idno type="wicri:Area/Main/Exploration">000537</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Focus on clinical outcomes of "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial".</title>
<author><name sortKey="Wambier, Carlos Gustavo" sort="Wambier, Carlos Gustavo" uniqKey="Wambier C" first="Carlos Gustavo" last="Wambier">Carlos Gustavo Wambier</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Dermatology, Brown University, Warren Alpert School of Medicine, Providence, Rhode Island. Electronic address: carlos_wambier@brown.edu.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Rhode Island</region>
<settlement type="city">Providence (Rhode Island)</settlement>
</placeName>
<wicri:cityArea>Department of Dermatology, Brown University, Warren Alpert School of Medicine, Providence</wicri:cityArea>
<orgName type="university">Université Brown</orgName>
</affiliation>
</author>
</analytic>
<series><title level="j">International journal of antimicrobial agents</title>
<idno type="eISSN">1872-7913</idno>
<imprint><date when="2021" type="published">2021</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anti-Bacterial Agents (therapeutic use)</term>
<term>Antimalarials (therapeutic use)</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>Azithromycin (therapeutic use)</term>
<term>COVID-19 (drug therapy)</term>
<term>COVID-19 (virology)</term>
<term>Clinical Trials as Topic (MeSH)</term>
<term>Drug Combinations (MeSH)</term>
<term>Drug Repositioning (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Hydroxychloroquine (therapeutic use)</term>
<term>SARS-CoV-2 (pathogenicity)</term>
<term>Uncertainty (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Antibactériens (usage thérapeutique)</term>
<term>Antipaludiques (usage thérapeutique)</term>
<term>Antiviraux (usage thérapeutique)</term>
<term>Association médicamenteuse (MeSH)</term>
<term>Azithromycine (usage thérapeutique)</term>
<term>Essais cliniques comme sujet (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Hydroxychloroquine (usage thérapeutique)</term>
<term>Incertitude (MeSH)</term>
<term>Repositionnement des médicaments (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Bacterial Agents</term>
<term>Antimalarials</term>
<term>Antiviral Agents</term>
<term>Azithromycin</term>
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>COVID-19</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>SARS-CoV-2</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antibactériens</term>
<term>Antipaludiques</term>
<term>Antiviraux</term>
<term>Azithromycine</term>
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>COVID-19</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Clinical Trials as Topic</term>
<term>Drug Combinations</term>
<term>Drug Repositioning</term>
<term>Humans</term>
<term>Uncertainty</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Association médicamenteuse</term>
<term>Essais cliniques comme sujet</term>
<term>Humains</term>
<term>Incertitude</term>
<term>Repositionnement des médicaments</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33408021</PMID>
<DateCompleted><Year>2021</Year>
<Month>01</Month>
<Day>14</Day>
</DateCompleted>
<DateRevised><Year>2021</Year>
<Month>03</Month>
<Day>10</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1872-7913</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>57</Volume>
<Issue>1</Issue>
<PubDate><Year>2021</Year>
<Month>Jan</Month>
</PubDate>
</JournalIssue>
<Title>International journal of antimicrobial agents</Title>
<ISOAbbreviation>Int J Antimicrob Agents</ISOAbbreviation>
</Journal>
<ArticleTitle>Focus on clinical outcomes of "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial".</ArticleTitle>
<Pagination><MedlinePgn>106175</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S0924-8579(20)30381-2</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijantimicag.2020.106175</ELocationID>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wambier</LastName>
<ForeName>Carlos Gustavo</ForeName>
<Initials>CG</Initials>
<AffiliationInfo><Affiliation>Department of Dermatology, Brown University, Warren Alpert School of Medicine, Providence, Rhode Island. Electronic address: carlos_wambier@brown.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>Int J Antimicrob Agents</MedlineTA>
<NlmUniqueID>9111860</NlmUniqueID>
<ISSNLinking>0924-8579</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000962">Antimalarials</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber>
<NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>83905-01-5</RegistryNumber>
<NameOfSubstance UI="D017963">Azithromycin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000962" MajorTopicYN="N">Antimalarials</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017963" MajorTopicYN="N">Azithromycin</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058492" MajorTopicYN="N">Drug Repositioning</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
<QualifierName UI="Q000472" MajorTopicYN="Y">pathogenicity</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D035501" MajorTopicYN="N">Uncertainty</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>03</Month>
<Day>21</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>08</Month>
<Day>14</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2021</Year>
<Month>1</Month>
<Day>7</Day>
<Hour>5</Hour>
<Minute>53</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2021</Year>
<Month>1</Month>
<Day>8</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2021</Year>
<Month>1</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">33408021</ArticleId>
<ArticleId IdType="pii">S0924-8579(20)30381-2</ArticleId>
<ArticleId IdType="doi">10.1016/j.ijantimicag.2020.106175</ArticleId>
<ArticleId IdType="pmc">PMC7779256</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Pediatr Cardiol. 2002 Jan-Feb;23(1):41-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11922507</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 Jul;56(1):105949</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Rhode Island</li>
</region>
<settlement><li>Providence (Rhode Island)</li>
</settlement>
<orgName><li>Université Brown</li>
</orgName>
</list>
<tree><country name="États-Unis"><region name="Rhode Island"><name sortKey="Wambier, Carlos Gustavo" sort="Wambier, Carlos Gustavo" uniqKey="Wambier C" first="Carlos Gustavo" last="Wambier">Carlos Gustavo Wambier</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000479 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000479 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidChloroV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:33408021
   |texte=   Focus on clinical outcomes of "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial".
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:33408021" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidChloroV1

This area was generated with Dilib version V0.6.38.
Data generation: Sat May 22 17:02:32 2021. Site generation: Sat May 22 17:06:52 2021

	Serveur d'exploration COVID et hydrochloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration COVID et hydrochloroquine

Focus on clinical outcomes of "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial".

Focus on clinical outcomes of "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial".

Source :

Descripteurs français

English descriptors

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki